饲料产品认证管理办法

第一章总则第一条为提高饲料质量安全卫生水平,规范饲料产品认证工作,促进饲料工业和养殖业的发展,维护人体健康,保护动物生命安全,根据《中华人民共和国认证认可条例》、《饲料和饲料添加剂管理条例》,制定本办法。     

饲料产品认证管理办法

第一条 为提高饲料质量安全卫生水平，规范饲料产品认证工作，促进饲料工业和养殖业的发展，维护人体健康，保护动物生命安全，根据《中华人民共和国认证认可条例》、《饲料和饲料添加剂管理条例》，制定本办法。     

饲料产品认证管理办法（国家认证认可监督委员会 农业部 制定）

第一条为提高饲料质量安全卫生水平，规范饲料产品认证工作，促进饲料工业和养殖业的发展，维护人体健康，保护动物生命安全，根据《中华人民共和国认证认可条例》、《饲料和饲料添加剂管理条例》，制定本办法。     

饲料产品认证管理办法

第一章 总则 第一条 为提高饲料质量安全卫生水平,规范饲料产品认证工作,促进饲料工业和养殖业的发展,维护人体健康,保护动物生命安全,根据《中华人民共和国认证认可条例》、《饲料和饲料添加剂管理条例》,制定本办法。 第二条 本办法所称的饲料产品认证,是指企业自愿申请,认证机构对饲料和饲料添加剂产品及其生产过程按照有关标准或者技术规范要求进行合格评定的活动。     

饲料和饲料添加剂生产许可管理办法

第一章总则第一条为加强饲料、饲料添加剂生产许可管理,维护饲料、饲料添加剂生产秩序,保障饲料、饲料添加剂质量安全,根据《饲料和饲料添加剂管理条例》,制定本办法。第二条在中华人民共和国境内生产饲料、饲料添加剂,应当遵守本办法。第三条饲料添加剂和添加剂预混合饲料生产许可证由农业部核发。单一饲料、浓缩饲料、配合饲料和精料补充料生产许可证由省级人民政府饲     

饲料添加剂和添加剂预混合饲料产品批准文号管理办法

第一条 根据《饲料和饲料添加剂管理条例》第九条规定,制定本办法。 第二条 在中华人民共和国境内从事饲料添加剂、添加剂预混合饲料生产、经营、监督、检验的单位和个人,应当遵守本办法。 第三条 本办法所称饲料添加剂是指饲料加工、制作、使用过程中添加的少量或微量物质。包括营养性饲料添加剂和一般饲料添加剂。生产和使用的饲料添加剂品种应当属于农业部公布的《允许使用的饲料添加剂     

饲料添加剂和添加剂预混合饲料产品批准文号管理办法

中华人民共和国农业部令　　　　　　　　　　第２３号《饲料添加剂和添加剂预混合饲料批准文号管理办法》，已于１９９９年１２月９日经农业部常务会议通过，现予以发布施行。部长陈耀邦一九九九年十二月十四日第一条根据《饲料和饲料添加剂管理条例》第九条规定，制定本办法。第二条在中华人民共和国境内从事饲料添加剂、添加剂预混合饲料生产、经营、监督、检验的单位和个人，应当遵守本办法。第三条本办法所称饲料添加剂是指饲料加工、制作、使用过程中添加少量或微量物质。包括营养性饲料添加剂和一般饲料添加剂。生产和使用的饲料添加…     

饲料添加剂和添加剂预混合饲料产品批准文号管理办法

中华人民共和国农业总令2012年第5号《饲料添加剂和添加剂预混合饲料产品批准文号管理办法》已经2012年农业部第6次常务会议审议通过,现予公布,自2012年7月1日起施行。部长:韩长赋二○一二年五月二日第一条为加强饲料添加剂和添加剂预混合饲料产品批准文号管理,根据《饲料和饲料添加剂管理条例》,制定本办法。第二条本办法所称饲料添加剂,是指在饲料     

饲料添加剂和添加剂预混合饲料产品批准文号管理办法

中华人民共和国农业部令第２３号《饲料添加剂和添加剂混合饲料批准文号管理办法》 ,已于１９９９年１２月９日经农业部常务会议通过 ,现予以发布施行。部长陈耀邦一九九九年十二月十四日第一条根据《饲料和饲料添加剂管理条例》第九条规定 ,制定本办法。第二条在中华人民共和国境内从事饲料添加剂、添加剂预混合饲料生产、经营、监督、检验的单位和个人 ,应当遵守本办法。第三条本办法所称饲料添加剂是指饲料加工、制作、使用过程中添加的少量或微量物质。包括营养性饲料添加剂和一般饲料添加剂。生产和使用的饲料添加剂品种应当属于农业部…     

饲料添加剂和添加剂预混合饲料生产许可证管理办法

中华人民共和国农业部令第24号《饲料添加剂和添加剂预混合饲料生产许可证管理办法》,已于1999年12月9日经农业部常务会议通过,现予发布施行。部长　陈耀邦一九九九年十二月十四日第一章　总　则　　第一条根据《饲料和饲料添加剂管理条例》第九条规定,制定本办法。第二条本办法所指饲料添加剂包括营养性饲料添加剂、一般饲料添加剂。本办法所称添加剂预混合饲料是指由两种或两种以上饲料添加剂加载体或稀释剂按一定比例配制而成的均匀混合物,在配合饲料中添加量不超过10%。第三条生产、使用的饲料添加剂品种应当属于农业部公布的《允许使用…     

高致病性禽流感免疫的管理环节

一 严管疫苗生产环节 兽用生物制品生产厂家多,品种较多,质量不一,免疫效果各异,特别是高致病性禽流感疫苗,由于生产时间较短,疫苗质量不够稳定,副作用较为严重,包装规格单一,技术服务滞后．严重地影响了高致病性禽流感的免疫效果。如有的厂家疫苗生产的批准文号和疫苗产品不相符。有的中试产品或有临时批准文号的疫苗,不按规定范围随意大面积推广,有的同一厂家生产的疫苗,不同批次质量不一,免疫效果差异较大。     

猪胴体分级标准初探

<正>猪胴体分级的目的是确定屠体某些特性,并根据这些特性指标决定屠体及其产品的价值,使产销双方有共同标准可以遵循,在公平合理交易原则下,防止产生纷争。良好的分级标准和制度能确实反映市场需要,进而敦促生产者谋求改进肉猪屠体品质。我国原有的猪胴体品质分级标准已经不适合使     

服务农业服务社会

在迎接新世纪,庆贺新千年的时候,饲料行业如同其他行业一样,也在筹划今后的发展问题。研究任何产业的发展,都要研究自身的特点,还要研究与其他产业的关联。饲料工业,是个关联性很强的产业。最明显的是,依托于农业,又服务于农业。饲料工业的原料,绝大部分直接来源于农业,没有农业作基础,就没有饲料工业;没有发达的农业,也就没有发达的饲料工业。因此,服务农业,是发展饲料工业的题中应有之义。民以食为天。服务于农业,服务于“菜篮子”工程,也就是服务于社会。我国饲料工业的发展,为农业,为养殖业,为人民生活的改善,做出了巨大的贡献。据国家…     

Transgenic pigs for xenotransplantation for humans]

Transgenic livestock have been generated via microinjection of DNA-constructs into pronuclei of zygotes. However, efficiency is low and only 1-3% transgenic offspring are to be obtained. Integration of the transgene occurs at random and expression is independent from the number of integrated copies but can be affected by the integration site. To overcome the shortage of human organs, transgenic pigs have been generated that express human complement regulatory genes. This approach enables to overcome the hyperacute rejection response as shown by an average survival rate (40-90 days) of the immunosuppressed primate recipients receiving a heart from a transgenic pig. It is expected that transgenic pigs would be available as organ donors in the next 5-10 years. A major prerequisite, however, is the prevention of the potential transfer of pathogenic microorganisms, in particular porcine endogenous retroviruses (PERV). Improvements of the efficiency in the generation of transgenic pigs will be achieved by the use of genetically modified donor cells in nuclear transfer technology (cloning).     

Strategies for Using eFSH for Superovulating Mares

The standard treatment for superovulation of mares is to administer equine follicle-stimulating hormone (eFSH) for 4 to 5 days to stimulate multiple follicles and human chorionic gonadotropin (hCG) to induce synchronous ovulations. Objectives of this study were: (1) to determine whether a short-term (3-day) eFSH treatment protocol would result in similar ovulation and embryo recovery rates compared with the standard eFSH protocol; (2) to determine the efficacy of a decreasing dose of eFSH (step-down protocol) on ovulation rate and embryo recovery; (3) to compare the efficacy of hCG and recombinant equine luteinizing hormone (reLH) for inducing ovulation in FSH-treated mares; and (4) to compare embryo recovery rates and embryo size when mares are flushed at 6.5 or 7.0 days after ovulation. Forty light-horse mares were used in 2005 (experiment 1) and 20 different mares were used in 2006 (experiment 2). In experiment 1, mares were randomly assigned to one of three treatment groups: (1) untreated controls, (2) standard eFSH treatment (12.5 mg intramuscularly twice daily), and (3) 3-day eFSH treatment. In experiment 2, mares were randomly assigned to one of four treatments: (1) untreated controls, (2) standard eFSH protocol, (3) 3-day eFSH treatment, and (4) step-down eFSH treatment (12.5 mg twice daily day 1, 8.0 mg twice daily day 2, 4.0 mg twice daily day 3). Within each treatment, mares were given either hCG (2,500 IU) or equine LH (750 mg, EquiPure LH; reLH) to induce synchronized ovulations. Embryo recovery was performed either 6.5 or 7.0 days after ovulation. In experiment 1, numbers of preovulatory follicles and ovulations were less for mares in the 3-day treatment group than the standard group, but were greater than for controls. Embryo recovery per flush was higher in the standard group (2.6) than the 3-day eFSH treatment (0.8) or control groups (0.8). In experiment 2, the number of preovulatory follicles and number of ovulations were greater in the standard and 3-day treatment groups than in control and step-down groups. The percent embryo recovery per ovulation and mean embryo grade were similar for all groups; however, the embryo recovery per flush was higher for mares in the standard treatment than controls (1.3 vs 0.6) but was similar to the 3-day (1.1) and step-down (0.8) treatments. Embryo recovery was similar for flushes performed on days 6.5 and 7.0 post-ovulation. The percentage of control mares ovulating within 48 hours in response to hCG or reLH was similar. In contrast, a higher percentage of eFSH-treated mares ovulated within 48 hours in response to reLH than hCG (92% vs 71%). In both years, the 3-day eFSH treatment protocol resulted in a greater number of preovulatory follicles and a greater number of ovulations than untreated controls. Unfortunately, the increased ovulation rate for mares administered eFSH for 3 days did not result in a greater number of embryos recovered per flush in either year. Use of a step-down eFSH treatment protocol resulted in fewer preovulatory follicles, fewer ovulations, and fewer embryos as compared with the standard eFSH treatment. In conclusion, the standard eFSH treatment resulted in a greater embryo recovery rate per cycle than either the 3-day or step-down treatment protocols. Recombinant equine LH was more effective than hCG in causing ovulation in eFSH-treated mares.